Omeros plans to price public offering of stock with a 30-day greenshoe

Cowen, Deutsche Bank assist; proceeds fund general corporate purposes

By Devika Patel

Knoxville, Tenn., June 26 - Omeros Corp. will price a public sale of common stock, according to a prospectus supplement filed Tuesday with the Securities and Exchange Commission. The deal will have a 30-day greenshoe for 15%.

Cowen and Co. and Deutsche Bank Securities are the joint bookrunning managers.

Proceeds will be used for general corporate purposes, including the clinical development of OMS302 and OMS103HP, research and development, preclinical studies and clinical trials, capital expenditures, working capital and advancing product candidates toward commercialization.

The company's stock (Nasdaq: OMER) closed at $13.24 per share on June 25.

Omeros is a biopharmaceutical company based in Seattle.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.